New type 2 diabetes drug approved in the US

The twice daily type 2 diabetes drug Jentadueto has been made available in tablet form on prescription in the United States following approval by the Food and Drug Administration (FDA).
The medicine, taken by diabetes patients to help manage their blood sugar levels, is produced by pharma giants Eli Lilly and Boehringer Ingelheim. It combines two separate diabetes drugs, the dipeptidyl peptidase-4 (DPP-4) inhibitor, linaglipti, and metformin, into a single tablet. Linagliptin is already sold independently in the US as Tradjenta 5mg once-daily tablets.
The prescription medicine is recommended to be taken with both diet and exercise to improve glycaemic control in adults suffering from type 2 diabetes when a treatment with both linagliptin and metformin is considered suitable.
The prescription drug should not be taken by people with either type 1 diabetes or diabetic ketoacidosis, and has a warning on its label about the potential risk of lactic acidosis, a complication from metformin accumulation during treatment.
Jentadueto offers doctors the ability to adjust the amount of metformin prescribed according to its effectiveness and tolerability, and is available in three dosage strengths, 2.5 mg linagliptin/500 mg metformin hydrochloride, 2.5 mg linagliptin/850 mg metformin hydrochloride and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

To Top